Phaseline

Targets › MYO7A

MYO7A (Unconventional myosin-VIIa): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Jul 2029.

Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. (UniProt, Q13402)

Open in Phaseline: the race on MYO7A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AAVantgarde Bio SrlAAVB-081
AAV gene therapy delivering MYO7A cDNA
MYO7APhase 1Usher Syndrome, Type 1BJul 2029

Conditions

Usher Syndrome, Type 1B (1)

Modalities

other (1)

Companies

AAVantgarde Bio Srl (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.